What Is REGN Fair Value?
Regeneron Pharmaceuticals (REGN) fair value estimate using multiple valuation models, updated daily.
As of July 16, 2026, Regeneron Pharmaceuticals (REGN) has a composite fair value estimate of $1,123.63 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $664.45, suggesting the stock is undervalued by 69.1%.
Data as of July 16, 2026 (today)
Composite Fair Value
Undervalued4 of 4 models$1,123.63
vs. current price of $664.45(+69.1%)
How Is REGN Fair Value Calculated?
Four independent models estimate what REGN is worth. Each uses different inputs and assumptions. The composite blends them by weight.
REGN Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$1,923.20
+189.4%Undervalued
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$394.04
-40.7%Overvalued
Inputs used
REGN Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$564.83
-15.0%Fair Value
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$525.64
-20.9%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $664.45 is 189.4% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $3.76B | $3.56B |
| Year 2 | $4.20B | $3.75B |
| Year 3 | $4.67B | $3.96B |
| Year 4 | $5.21B | $4.17B |
| Year 5 | $5.80B | $4.39B |
| Year 6 | $6.47B | $4.63B |
| Year 7 | $7.21B | $4.88B |
| Year 8 | $8.03B | $5.14B |
| Year 9 | $8.95B | $5.42B |
| Year 10 | $9.97B | $5.71B |
| Terminal Value | $316.66B | $181.43B |
What Are REGN's Key Financial Metrics?
Earnings & Growth
Current Price
$664.45
EPS (TTM)
$41.46
Forward P/E
12.1
Profit Margin
29.6%
Cash & Balance Sheet
Free Cash Flow
3.3B
EBITDA
4.4B
Book Value
$308.33
Total Debt
2.7B
What Do Analysts Say About REGN?
Low
$641.00
Average
$820.72
High
$1,000.00
Upside
+23.5%
REGN Fair Value FAQ
What is the fair value of REGN?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), REGN's estimated fair value is $1,123.63. The stock is currently trading at $664.45, which makes it undervalued by our analysis.
How is REGN's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is REGN overvalued or undervalued?
Based on our analysis, REGN is undervalued. The current price of $664.45 is 69.1% below our estimated fair value of $1,123.63.
What do Wall Street analysts say about REGN?
27 analysts cover Regeneron Pharmaceuticals with a consensus rating of "Buy." The average price target is $820.72, ranging from $641.00 to $1,000.00. This implies 23.5% upside from the current price.